Alzheimer’s
Top Ten most popular articles on Pharmafile.com this week
January 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten
It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …
Another Alzheimer’s drug bites the dust in P3
January 12, 2018Medical Communications, Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical
It’s been a terrible week for Alzheimer’s disease research, after Pfizer shuttered its neuroscience unit and
New project examining FDA-approved drugs for Alzheimer’s, worries over research remains
January 10, 2018Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical
It’s been a gloomy period for research into Alzheimer’s disease treatments in the last week, Pfizer announced it would be …
Over-the-counter multinutrient drink could have beneficial impact on Alzheimer’s, new study reveals
October 31, 2017Manufacturing and Production, Research and Development Alzheimer's, Fortasyn Connect, Souvenaid, dementia
LipiDiDiet, a European project investigating “the impact of nutritional lipids on neuronal and cognitive performance in ageing, Alzheimer’s disease and …
Research finds blood-thinners protect against dementia
October 25, 2017Research and Development Alzheimer's, anticoagulant, biotech, dementia, drugs, pharma, pharmaceutical
Blood-thinning drugs are commonly used to reduce stroke risk in patients with atrial fibrillation (AF) but research from the Karolinska …
Axovant shares capitulate after Alzheimer’s drug failure
September 26, 2017Research and Development Alzheimer's, Axovant, biotech, drugs, pharma, pharmaceutical
Axovant Sciences was set up with just one drug candidate in its portfolio, and a risky one, at that. The …
Alzheimer’s disease: Fighting back against a growing threat
September 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Alzheimer's UK, dementia, life sciences, pharma
September marks Alzheimer’s Awareness Month, a crucial calendar period as the global threat of the disease slowly grows. To mark …
Stomach acid drugs do not increase Alzheimer’s risk, study confirms
August 7, 2017Research and Development, Sales and Marketing Alzheimer's, dementia, drugs, healthcare, lansoprazole, life sciences, medicine, omeprazole, pharma, pharmaceuticals, proton pump inhibitors
A new study from the University of Eastern Finland has indicated that the use of proton pump inhibitors such as …
Enzyme able to untangle protein aggregates associated with Alzheimer’s
June 29, 2017Research and Development Alzheimer's, Parkinson's
There are currently no effective treatments for neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease. This is presently a pressing …
Immune system attacks the brain in Alzheimer’s, study suggests
June 22, 2017Research and Development Alzheimer's
New research has identified direct evidence that the body’s immune system attacks the brain in Parkinson’s disease, seemingly confirming a …
Cuba looks to begin trials of new neuroprotective treatment for Alzheimer’s
May 16, 2017Manufacturing and Production, Research and Development Alzheimer's, Cuba, dementia
The health care system in Cuba is widely held up to be a model of innovation; despite severe economic sanctions …
New drug study successfully halts neurodegeneration in mice
April 20, 2017Research and Development Alzheimer's, Parkinson's, trazodone
A team of scientists at Medical Research Council’s (MRC) Toxicology Unit in Leicester, UK have identified methods to prevent neurodegeneration …
Genentech plans second Phase 3 Alzheimer’s trial following endpoint failures
March 20, 2017Research and Development, Sales and Marketing Alzheimer's, Genentech, Roche
Genentech, Roche’s biotech group, has announced its plans to conduct a second Phase 3 study for crenezumab, its anti-Abeta antibody …
MSD’s Alzheimer’s drug failure undermines potential treatment pathway
February 15, 2017Research and Development Alzheimer's, MSD, Merck
MSD, known as Merck in North America, has announced that it has been forced to cancel a Phase 2/3 trial …
Two Phase 3 failures put nail in the coffin for Lundbeck Alzheimer’s drug
February 9, 2017Research and Development, Sales and Marketing Alzheimer's, Lundbeck, idalopirdine
Danish pharma firm Lundbeck has announced the failure of two Phase 3 trials investigating its experimental Alzheimer’s treatment idalopirdine; the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
